📊 AUPH Key Takeaways
Is Aurinia Pharmaceuticals Inc. (AUPH) a Good Investment?
Aurinia demonstrates exceptional profitability fundamentals with 53.3% operating margins and 44.2% net margins, coupled with solid 20.4% YoY revenue growth. The balance sheet is fortress-like with zero meaningful debt, strong liquidity (5.55x current ratio), and consistent free cash flow generation ($32.6M FCF). Primary concerns center on modest capital efficiency (6.1% ROE) and pharmaceutical sector risks.
Aurinia shows strong underlying fundamentals with double-digit revenue growth, high operating profitability, and robust free cash flow generation. The balance sheet is exceptionally healthy, with no meaningful leverage and strong liquidity, although the outsized net income and net margin suggest at least part of recent earnings strength may be driven by non-recurring or below-the-line items.
Aurinia Pharmaceuticals Inc. Key Strengths (AUPH)
- Exceptional profitability margins (53.3% operating, 44.2% net) well above pharma industry averages
- Strong balance sheet with zero debt (D/E 0.00x), excellent liquidity (5.55x current ratio), and $567.6M equity base
- Consistent free cash flow generation (41.9% FCF margin) indicating sustainable business model
- Solid revenue growth at 20.4% YoY with profitability scaling
- No financial distress indicators (16.7x interest coverage, manageable debt load)
- Revenue growth remains solid at 20.4% year over year, indicating continued commercial momentum.
- Operating margin of 37.1% and free cash flow margin of 47.9% point to strong operating efficiency and cash conversion.
- Balance sheet strength is high, with a 5.25x current ratio, substantial cash, and effectively no long-term debt.
AUPH Stock Risks: Aurinia Pharmaceuticals Inc. Investment Risks
- Low return on equity (6.1%) and ROA (4.7%) suggest inefficient capital deployment despite strong margins
- Pharmaceutical company inherent risks: clinical trial failures, regulatory setbacks, patent cliffs
- Modest cash position ($40.7M) relative to asset base may constrain growth investments
- Missing gross margin data limits visibility into production cost structure
- Relatively small revenue base ($77.7M) with limited scale
- Net income growth far exceeds revenue growth, which raises concern that recent earnings may include one-time gains and may not fully reflect recurring profitability.
- The absence of gross margin and capital expenditure detail limits visibility into core product economics and reinvestment needs.
- As a pharmaceutical company, fundamentals may be vulnerable to product concentration, regulatory outcomes, and commercialization execution.
Key Metrics to Watch
- Revenue growth sustainability and gross margin trends
- Operating cash flow trajectory and capital allocation strategy
- Return on equity improvement as company scales
- R&D pipeline progress and clinical trial outcomes
- Sustainable operating income and operating margin excluding one-time items
- Revenue growth and operating cash flow consistency over the next few filings
Aurinia Pharmaceuticals Inc. (AUPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 41.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.55x current ratio provides a solid financial cushion.
AUPH Profit Margin, ROE & Profitability Analysis
AUPH vs Healthcare Sector: How Aurinia Pharmaceuticals Inc. Compares
How Aurinia Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aurinia Pharmaceuticals Inc. Stock Overvalued? AUPH Valuation Analysis 2026
Based on fundamental analysis, Aurinia Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aurinia Pharmaceuticals Inc. Balance Sheet: AUPH Debt, Cash & Liquidity
AUPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aurinia Pharmaceuticals Inc.'s revenue has grown significantly by 465% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.54 indicates the company is currently unprofitable.
AUPH Revenue Growth, EPS Growth & YoY Performance
AUPH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $62.5M | $23.3M | $0.16 |
| Q3 2025 | $67.8M | $722.0K | $0.03 |
| Q2 2025 | $57.2M | $722.0K | $0.01 |
| Q1 2025 | $50.3M | -$10.7M | $-0.07 |
| Q3 2024 | $54.5M | $4.3M | $0.03 |
| Q2 2024 | $41.5M | $722.0K | $0.01 |
| Q1 2024 | $34.4M | -$10.7M | $-0.07 |
| Q3 2023 | $54.5M | -$9.0M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aurinia Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
AUPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aurinia Pharmaceuticals Inc. (CIK: 0001600620)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AUPH
What is the AI rating for AUPH?
Aurinia Pharmaceuticals Inc. (AUPH) has a Combined AI Grade of A from Claude (A) and ChatGPT (A) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AUPH's key strengths?
Claude: Exceptional profitability margins (53.3% operating, 44.2% net) well above pharma industry averages. Strong balance sheet with zero debt (D/E 0.00x), excellent liquidity (5.55x current ratio), and $567.6M equity base. ChatGPT: Revenue growth remains solid at 20.4% year over year, indicating continued commercial momentum.. Operating margin of 37.1% and free cash flow margin of 47.9% point to strong operating efficiency and cash conversion..
What are the risks of investing in AUPH?
Claude: Low return on equity (6.1%) and ROA (4.7%) suggest inefficient capital deployment despite strong margins. Pharmaceutical company inherent risks: clinical trial failures, regulatory setbacks, patent cliffs. ChatGPT: Net income growth far exceeds revenue growth, which raises concern that recent earnings may include one-time gains and may not fully reflect recurring profitability.. The absence of gross margin and capital expenditure detail limits visibility into core product economics and reinvestment needs..
What is AUPH's revenue and growth?
Aurinia Pharmaceuticals Inc. reported revenue of $77.7M.
Does AUPH pay dividends?
Aurinia Pharmaceuticals Inc. does not currently pay dividends.
Where can I find AUPH SEC filings?
Official SEC filings for Aurinia Pharmaceuticals Inc. (CIK: 0001600620) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AUPH's EPS?
Aurinia Pharmaceuticals Inc. has a diluted EPS of $0.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AUPH's fundamental grade?
Based on our AI fundamental analysis in June 2026, Aurinia Pharmaceuticals Inc. has a A grade with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is AUPH stock overvalued or undervalued?
Valuation metrics for AUPH: ROE of 6.1% (sector avg: 15%), net margin of 44.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AUPH's AI grade for 2026?
Our dual AI analysis gives Aurinia Pharmaceuticals Inc. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is AUPH's free cash flow?
Aurinia Pharmaceuticals Inc.'s operating cash flow is $32.6M, with capital expenditures of N/A. FCF margin is 41.9%.
How does AUPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 44.2% (avg: 12%), ROE 6.1% (avg: 15%), current ratio 5.55 (avg: 2).